feraccru
norgine b.v. - dzelzs maltols - anēmija, dzelzs deficīts - antianēmiski līdzekļi - feraccru ir norādīts ārstēšanai pieaugušajiem dzelzs deficīts.
rosacta krēms
medis gmbh, austria - rozmarīna ēteriskā eļcļca - krēms - 100 mg/g
medisoya+ (paziņots 2012.) kapsula
sabiedrības “arkopharma” grupa “nutripharma ltd” - kapsula
medisoya (paziņots 2011.) kapsula
sabiedrības “arkopharma” grupa “nutripharma ltd” - kapsula
medisoya kapsula
sabiedrības ″arkopharma″ grupa ″nutripharma ltd″ - kapsula
nutriflex omega 56/144 emulsija infūzijām
b.braun melsungen ag, germany - isoleucinum, leucinum, lysinum, methioninum, phenylalaninum, threoninum, tryptophanum, valinum, argininum, histidinum, alaninum, acidum asparticum, acidum glutamicum, glycinum, prolinum, serinum, natrii hydroxidum, natrii chloridum, natrii acetas trihydricus, kalii acetas, magnesii acetas tetrahydricus, calcii chloridum dihydricum, glucosum monohydricum, natrii dihydrogenophosphas dihydricus, zinci acetas dihydricus, triglycerida saturata media, soiae oleum, omega-3 acidorum triglycerida - emulsija infūzijām
aktivĒtĀ ogle ms tablete
medisorb, as - tablete
imjudo
astrazeneca ab - tremelimumab - carcinoma, hepatocellular - antineoplastiski līdzekļi - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.
yescarta
kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - antineoplastiski līdzekļi - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.
fitline® deoral (paziņots 2008.) kapsula
medisana gmbh - kapsula